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Background: IFNγ-producing CD4+CD25+Foxp3+ PBL represent a subtype of iTreg that are associated with good
long-term graft outcome in renal transplant recipients and suppress alloresponses in-vitro. To study the mechanism
of immunosuppression, we attempted to block cell surface receptors and thereby inhibited the function of this
iTreg subset in-vitro using monoclonal antibodies and recombinant proteins.
Methods: PBL of healthy control individuals were stimulated polyclonally in-vitro in the presence of monoclonal
antibodies or recombinant proteins against/of CD178, CD152, CD279, CD28, CD95, and HLA-DR. Induction of
IFNγ+ iTreg and proliferation of effector cells was determined using four-color fluorescence flow cytometry.
Blockade of iTreg function was analyzed using polyclonally stimulated co-cultures with separated
CD4+CD25+CD127-IFNγ+ PBL.
Results: High monoclonal antibody concentrations inhibited the induction of CD4+CD25+Foxp3+IFNγ+ PBL
(anti-CD152, anti-CD279, anti-CD95: p < 0.05) and CD4+CD25+CD127-IFNγ+ PBL (anti-CD178, anti-CD152, anti-CD279,
anti-CD95: p < 0.05). Effector cell proliferation increased with increasing antibody concentrations in culture medium
(anti-CD178 and anti-CD279: p < 0.05). Conversely, high concentrations of recombinant proteins induced formation
of CD4+CD25+Foxp3+IFNγ+ PBL (rCD152 and rCD95: p < 0.05) and decreased cell proliferation dose-dependently
(rCD178 and rCD95: p < 0.05). Our data suggest an inverse association of iTreg induction with effector cell
proliferation in cell culture which is dependent on the concentration of monoclonal antibodies against iTreg
surface determinants. 3-day co-cultures of polyclonally stimulated PBL with separated CD4+CD25+CD127-IFNγ+
PBL showed lower cell proliferation than co-cultures with CD4+CD25+CD127-IFNγ- PBL (p < 0.05). Cell proliferation
increased strongly in CD4+CD25+CD127-IFNγ- PBL-containing co-cultures in the presence of monoclonal antibody
(anti-CD28, anti-CD152, anti-CD279: p < 0.05) but remained low in co-cultures with CD4+CD25+CD127-IFNγ+
PBL (with the exception anti-CD28 monoclonal antibody: p < 0.05). Monoclonal antibodies prevent iTreg induction
in co-cultures with CD4+CD25+CD127-IFNγ- PBL but do not efficiently block suppressive iTreg function in
co-cultures with CD4+CD25+CD127-IFNγ+ PBL.
Conclusions: CD178, CD152, CD279, CD28, CD95, and HLA-DR determinants are important for induction and
suppressive function of IFNγ+ iTreg.
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Recently, we reported that CD4+CD25+Foxp3+IFNγ+
PBL were more frequently detectable in renal transplant
recipients with good than in recipients with impaired
long-term graft function [1]. IFNγ-secreting CD4+CD25+
Foxp3+ iTreg are usually undetectable in the peripheral
blood of healthy individuals [1,2]. CD4+CD25+Foxp3+
IFNγ+ PBL separated from primary MLC were shown to
inhibit allogeneic secondary MLC responses mainly anti-
gen-unspecifically, but in part also antigen-specifically
[2-7]. Separated CD4+CD25+IFNγ+ co-expressed Foxp3,
IL4, IL10, and TGFß intracellularly, suggesting that re-
lease of these immunosuppressive cytokines is involved
in the immunosuppressive mechanism of IFNγ+ iTreg
[2]. Using polyclonally stimulated cell cultures, we
showed that CD4+CD25+Foxp3+, CD4+CD25+IFNγ+ and
CD4+IFNγ+Foxp3+ PBL co-expressed CD178, CD28,
CD95, HLA-DR, CD152, and CD279 [4]. Our current
work addresses the hypothesis that these cell surface
determinants, representing receptors involved in cell-cell
interactions, contribute to immunosuppression mediated
by this particular iTreg subset. To address this question,
we attempted to block these cell surface receptors and
their ligands using monoclonal antibodies and recombin-
ant proteins. We studied two different subsets of IFNγ-
secreting iTreg subsets, namely CD4+CD25+Foxp3+
IFNγ+ and CD4+CD25+CD127-IFNγ+ iTreg. Because it
was shown that CD4+CD25+Foxp3+ and CD4+CD25+
CD127- iTreg subsets overlap and represent in part dif-
ferent iTreg subpopulations [8], we investigated both
subsets and particular those cells that produce intracel-
lular IFNγ.
Results
We studied whether monoclonal antibodies or recom-
binant proteins reactive with cell surface determinants
affect induction of CD4+CD25+Foxp3+IFNγ+ and CD4+
CD25+CD127-IFNγ+ PBL or cell proliferation in-vitro.
PBL of 5 healthy control individuals (HC1-HC5) were
separated from heparinized whole blood and stimulated
for 16 h using PMA/Ionomycin (iTreg induction) or for
3 days using PHA (cell proliferation) in the presence of
monoclonal antibodies against, or recombinant proteins
of, CD28, CD95, CD152, CD178, CD278, and HLA-DR.
CD4+CD25+Foxp3+IFNγ+ and CD4+CD25+CD127-IFNγ+
PBL as well as proportions of proliferating lymphoblasts
with low CFSE staining were determined.
Monoclonal antibodies against CD28, CD95, CD152,
CD178, CD278, and HLA-DR
Anti-CD178, anti-CD152, anti-CD279, anti-CD95, and
anti-HLA-DR but not anti-CD28 monoclonal antibody
inhibited the induction of CD4+CD25+Foxp3+IFNγ+ PBL
as compared to cell cultures without monoclonalantibody (all p < 0.05). Inhibition was dose-dependent
and increased in parallel with antibody concentration in
the cell culture (CD4+CD25+Foxp3+IFNγ+ PBL: anti-
CD152, anti-CD279, and anti-CD95: all p < 0.05; CD4+
CD25+CD127-IFNγ+ PBL: anti-178, anti-CD152, anti-
CD279, and anti-CD95: all p < 0.05) (Figures 1a, b).
Conversely, cell proliferation was lower in cell cul-
tures with than in cultures without monoclonal antibody
(p < 0.05; exception: anti-CD28) (Figure 1c). Cell prolif-
eration increased with increasing antibody concentration
in culture (anti-CD178 and anti-CD279: p < 0.05; anti-
CD152 and anti-DR: p = 0.080). It appears that mono-
clonal antibody blocks iTreg induction and function
dose-dependently and abrogates inhibition of cell prolif-
eration in culture.
Recombinant CD28, CD95, CD152, CD178, and CD278
Exposure to recombinant proteins induced the forma-
tion of CD4+CD25+Foxp3+IFNγ+ PBL (rCD152 and
rCD95: p < 0.05; rCD28: p = 0.080) (Figures 2a, b) and
was associated with decreased cell proliferation dose-
dependently (rCD178 and rCD95: p < 0.05) (Figure 2c).
Next, we tried to block the suppressive function of
separated pre-activated CD4+CD25+CD127-IFNγ+ PBL
in polyclonally stimulated co-cultures using monoclonal
antibodies against cell surface determinants of separated
IFNγ+ iTreg.
Co-cultures with separated CD4+CD25+CD127-IFNγ+ PBL
in the presence of monoclonal antibodies against CD28,
CD95, CD152, CD178, CD278, and HLA-DR
PBL of 9 healthy controls (HC1-HC9) were separated
from heparinized whole blood and stimulated for 16 h
using PMA/Ionomycin. CD4+CD25+CD127-IFNγ+ PBL
were separated from CD4+CD25+CD127-IFNγ- PBL and
each of the two cell fractions was added to co-cultures
of autologous PBL stimulated with PMA/Ionomycin for
another 3 days in the presence or absence of monoclonal
antibodies against CD28, CD95, HLA-DR, CD152,
CD178, or CD279 (Figure 3).
3-day co-cultures with separated CD4+CD25+CD127-
IFNγ+ PBL showed lower cell proliferation than co-
cultures with CD4+CD25+CD127-IFNγ- PBL (p = 0.011).
Cell proliferation increased in CD4+CD25+CD127-IFNγ-
PBL-containing co-cultures in the presence of anti-
CD28, anti-CD152, or anti-CD279 monoclonal antibody
(with vs without mab: CD28 p = 0.015, CD152 p =
0.028, CD279 p = 0.046, CD178 p = 0.066, CD95 p =
0.066, and HLA-DR p = n.s.) whereas in co-cultures with
CD4+CD25+CD127-IFNγ+ PBL cell proliferation was
consistently low, with the exception of co-cultures with
anti-CD28 monoclonal antibody which showed
increased proliferation (p = 0.011). Notably, all cultures
























































































































































































































































































































































































































Figure 1 (See legend on next page.)
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Figure 1 Induction of CD4+CD25+Foxp3+IFNγ+ and CD4+CD25+CD127-IFNγ+ PBL and cell proliferation in the presence of
PMA/Ionomycin and monoclonal antibodies against cell surface molecules. (a, b) PBL of 5 healthy control individuals (HC1-HC5) were
incubated in medium or stimulated with PMA/Ionomycin for 16 h in the presence of monoclonal antibodies against CD178, CD152, CD279, CD28,
CD95, and HLA-DR in final concentrations of 0.1 μg/ml and 1 μg/ml. The assay was measured using four-color fluorescence flow cytometry.
Compared to PMA-Ionomycin-stimulated cell cultures without monoclonal antibody, addition of anti-CD178, anti-CD152, anti-CD279, anti-CD95,
and anti-HLA-DR monoclonal antibody blocked induction of CD4+CD25+Foxp3+IFNγ+ PBL (p < 0.05) but not induction of CD4+CD25+CD127-IFNγ+
PBL (p = n.s.). When cell cultures with a 1-log difference in antibody concentration were compared, higher concentrations of anti-CD152,
anti-CD279, and anti-95 monoclonal antibody blocked induction of CD4+CD25+Foxp3+IFNγ+ PBL (p < 0.05) whereas higher anti-CD178,
anti-CD152, anti-CD279, and anti-CD95 concentrations blocked induction of CD4+CD25+CD127-IFNγ+ PBL (p < 0.05) compared to lower
concentrations of these antibodies in the cell cultures. (c) PBL of 5 healthy control individuals (HC1-HC5) were incubated in medium or
stimulated with PHA for 3 days in the presence of monoclonal antibodies against CD178, CD152, CD279, CD28, CD95, and HLA-DR in final
concentrations of 0.1 μg/ml and 1 μg/ml. The proportion of CFSElow PBL was determined using flow cytometry. With the exception of anti-CD28,
all monoclonal antibodies reduced cell proliferation (all p < 0.05) and cell proliferation tend to normalize in the presence of high antibody
concentrations, especially of anti-CD178 and anti-CD279 (p < 0.05). In the figure, statistical significant differences of assays with vs without
monoclonal antibodies are indicated by lines, whereas statistical significant differences of assays with low vs high monoclonal antibody
concentrations are indicated by arrows. Data are given as mean±SD. *p < 0.05.
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with CD4+CD25+CD127-IFNγ- PBL (CD178 p = 0.008,
HLA-DR p = 0.008, CD28 p = 0.015, CD95 p = 0.015,
CD152 p = 0.028, CD279 p = 0.028) (Figure 3). It
appears that monoclonal antibodies prevented iTreg in-
duction in co-cultures with CD4+CD25+CD127-IFNγ-
PBL, allowing strong effector cell proliferation, whereas
monoclonal antibodies did not block suppressive iTreg
function efficiently in CD4+CD25+CD127-IFNγ+ PBL-
containing co-cultures, resulting in no or only moderate
increases of effector cell proliferation.
In a separate experiment with PBL stimulated for
16 h using PMA/Ionomycin, CD4+CD25+Foxp3+CD127-
IFNγ+ PBL were shown to co-express CD178, CD152,
CD279, CD28, CD95, HLA-DR, IL4, IL10, and TGFß
(Figure 4). The data suggest that (a) CD4+CD25+Foxp3+
CD127-IFNγ+ PBL co-express the corresponding target
structure for the monoclonal antibodies and (b) that
CD4+CD25+Foxp3+CD127-IFNγ+ PBL might exert im-
munosuppression by both cell-cell contact and secretion
of immunosuppressive cytokines. Figure 5 shows that
approximately 0.5% of CD4+CD25+IFNγ+Foxp3+ and
0.7% of CD4+CD25+IFNγ+CD127- iTreg co-expressed
simultaneously the immunosuppressive cytokines TGFß
as well as IL10 intracellularly, and 5% of CD4+CD25+
IFNγ+Foxp3+ and 14% of CD4+CD25+IFNγ+CD127-
iTreg produced TGFß but not IL10 (all percentages with
respect to total of CD4+ PBL in the cell culture).
Discussion
In previous experiments, we were able to induce CD4+
CD25+Foxp3+IFNγ+ PBL by PMA/Ionomycin stimula-
tion in-vitro and these iTreg were shown to suppress
activation of responder cells in secondary MLC mainly
antigen-unspecifically, although the strongest suppres-
sion was seen in antigen-specific settings [2,3]. Induc-
tion of CD4+CD25+Foxp3+IFNγ+ PBL peaked at 6 h of
PMA/Ionomycin stimulation and decreased thereaftergradually [2]. Furthermore, we were able to show co-
expression of CD178, CD28, CD95, HLA-DR, CD152,
and CD279 on polyclonally stimulated CD4+CD25+
Foxp3+, CD4+CD25+IFNγ+ and CD4+Foxp3+IFNγ+ PBL
[4]. We hypothesized that interaction of at least some of
these cell surface receptors with their ligands might con-
tribute to immunosuppressive function. In the present
study, we studied whether blocking of these receptors
affects induction and immunosuppressive function of
IFNγ+ iTreg in-vitro.
We found that induction of IFNγ+ iTreg was pre-
vented in the presence of monoclonal antibodies against
CD28, CD95, CD152, CD178, CD278, and HLA-DR,
whereas recombinant proteins of these determinants
induced IFNγ+ iTreg. The frequency of IFNγ+ iTreg was
inversely associated with the cell proliferation rate dur-
ing 3-day cell culture. When CD4+CD25+CD127-IFNγ+
PBL were separated and added to autologous PBL, they
prevented cell proliferation; in contrast, addition of sepa-
rated CD4+CD25+CD127-IFNγ- PBL increased prolifera-
tion in cell co-cultures. Monoclonal antibodies increased
cell proliferation more markedly in cell cultures contain-
ing CD4+CD25+CD127-IFNγ- PBL than in cell cultures
containing CD4+CD25+CD127-IFNγ+ PBL. It thus
appears that monoclonal antibodies prevented iTreg in-
duction in co-cultures with separated CD4+CD25+
CD127-IFNγ- PBL, allowing strong effector cell prolife-
ration, whereas monoclonal antibodies did not block
suppressive iTreg function efficiently in co-cultures con-
taining separated CD4+CD25+CD127-IFNγ+ PBL, result-
ing in no or only moderate increases of effector cell
proliferation. In previously published experiments with
secondary MLC and CFSE-stained responder cells,
addition of CD4+CD25+IFNγ+ PBL separated from pri-
mary MLC inhibited the responder cell proliferation,
determined as CFSElow responder cells, stronger than
CD4+CD25+IFNγ- PBL remaining after separation, thus

























































































































































































































































































































Figure 2 (See legend on next page.)
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Figure 2 Induction of CD4+CD25+Foxp3+IFNγ+ and CD4+CD25+CD127-IFNγ+ PBL and cell proliferation in the presence of PMA/
Ionomycin and recombinant proteins against cell surface molecules. (a, b) PBL of 5 healthy control individuals (HC1-HC5) were incubated in
medium or stimulated with PMA/Ionomycin for 16 h in the presence of recombinant rCD178, rCD152, rCD279, rCD28, and rCD95 in final
concentrations of 0.1 μg/ml and 1 μg/ml. Then, assay was measured using four-color fluorescence flow cytometry. Proportions of
CD4+CD25+Foxp3+IFNγ+ and CD4+CD25+CD127-IFNγ+ PBL were calculated as proportion of all cultured CD4+ PBL. rCD28 reduced induction of
CD4+CD25+Foxp3+IFNγ+ PBL (p < 0.05). Higher concentrations of recombinant proteins tend to increase iTreg induction, especially of rCD152 and
rCD95 (p < 0.05). In the presence of rCD95, CD4+CD25+CD127-IFNγ+ PBL increased strongly (with vs without rCD95: p < 0.05). (c) PBL of 5 healthy
control individuals (HC1-HC5) were incubated in medium or stimulated with PHA for 3 days in the presence of recombinant rCD178, rCD152,
rCD279, rCD28, and rCD95 in final concentrations of 0.1 μg/ml and 1 μg/ml. Then, proportion of CFSElow PBL was determined using flow
cytometry. rCD178 and rCD95 reduced cell proliferation strongly (p < 0.05). Data are given as mean±SD.
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that cell cultures containing anti-CD28 monoclonal anti-
body showed increased induction of CD4+CD25+Foxp3+
IFNγ+ and CD4+CD25+CD127–IFNγ+ PBL (Figure 1a,
b), increased proliferation of CFSE-labelled responder
cells (Figure 1c), and increased activation/proliferation
when co-cultured with CD4+CD25+Foxp3+IFNγ+ PBL































































































































































Figure 3 Functional inhibition of iTreg by monoclonal antibodies aga
separated from heparinized whole blood and incubated for 16 h with med
separated from CD4+CD25+CD127-IFNγ- PBL and both cell fractions were a
another 3 days in the absence or presence of monoclonal antibodies again
CD95, and HLA-DR. Cell proliferation was measured as counts per minute (
CD4+CD25+CD127-IFNγ+ PBL showed lower cell proliferation than co-cultur
monoclonal antibodies against CD28, CD152 and CD279 increased cell pro
(p < 0.05). Of cell cultures with CD4+CD25+CD127-IFNγ+ PBL, only those wi
proliferation (p < 0.05). Data are given as mean±SD. *p < 0.05.monoclonal antibodies. We speculate that anti-CD28
monoclonal antibody amplifies cell activation in poly-
clonally stimulated cell cultures and induces prolifera-
tion of both IFNγ-secreting CD4+CD25+Foxp3+/ CD4+
CD25+CD127- PBL (Figures 1a, c) as well as responder
T cells (Figure 1c, 3). In summary, CD178, CD152,
CD279, CD28, CD95, and HLA-DR determinants were
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Figure 4 (See legend on next page.)
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Figure 4 Co-expression of CD178, CD152, CD279, CD28, CD95, HLA-DR, IL4, IL10, and TGFß on/in CD4+CD25+Foxp3+CD127-IFNγ+ iTreg.
PBL of 3 healthy control individuals were stimulated for 16 h using PMA/Ionomycin. Lymphocytes were determined in a FSC/SSC dot plot using
six-color-fluorescence flow cytometry. Gates for fluorochrome-labeled monoclonal antibodies were defined using appropriate isotype controls
that were adjusted to <1% positive cells in the corresponding quadrants. Based on these isotype controls, CD4+CD25+Foxp3+CD127-IFNγ+ PBL
were determined and co-expression of CD178, CD152, CD279, CD28, CD95, HLA-DR, IL4, IL10, and TGFß was analyzed. Figure (a) depicts the
gating strategy, Figure (b) summarizes the results of the 3 healthy controls. Data are given as mean±SD. Unstim = incubated in medium,
stimulated = incubated in PMA/Ionomycin.
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and HLA-DR determinants prevents induction of IFNγ-
producing iTreg during polyclonal stimulation and
induces effector cell proliferation dose-dependently. Re-
combinant proteins show the reverse effect. It therefore
can be concluded that interaction of CD178, CD152,
CD279, CD28, CD95, and HLA-DR determinants on
CD4+CD25+Foxp3+IFNγ+ and CD4+CD25+CD127-IFNγ+
PBL are essential for the suppressive function of these
IFNγ-producing iTreg subsets.
Our findings are in line with the findings of other
investigators. Strong CD28 co-stimulation suppressed
induction of Treg from naïve precursors through Lck
signaling and provided a rational for promoting T-cell
immunity or tolerance by regulating Treg through tar-
geting CD28 signaling [9]. CD152 (CTLA-4) controls
homeostasis and suppressive capacity of regulatory T




































Figure 5 Simultaneous co-expression of TGFß and IL10 in CD4+CD25+
control individuals were stimulated for 16 h using PMA/Ionomycin. Simulta
and CD4+CD25+IFNγ+CD127- iTreg was determined using six-color flow cyt
CD4+CD25+IFNγ+CD127- iTreg co-expressed the immunosuppressive cytokine
and 14% of CD4+CD25+IFNγ+CD127- iTreg produced TGFß but not IL10 (all pe
given as mean±SD. Unstim = incubated in medium, stimulated = incubated iin impairment of the suppressive capacity of Treg [10].
Expression of CD152 on Treg serves to control T cell
proliferation, to confer resistance against activation-
induced cell death, and to maintain the suppressive
function of Treg [10]. Distinctive characteristics of PD-1
expression on peripheral CD4+CD127lowCD25highFoxp3+
Treg in chronic HCV infection were associated with
impaired adaptive immunity as well as viral long-term
persistence [11]. In a mouse model, administration of
CD279 monoclonal antibody CT-011 prolonged Treg in-
hibition induced by low-dose cyclophosphamide, leading
to a sustainable synergistic decrease of splenic and
tumor-infiltrated Treg [12]. This strategy led to
complete regression of established tumors in a signifi-
cant percentage of treated animals, with survival pro-
longation [12]. Human Treg express Fas as well as FasL
and either kill activated T effector lymphocytes and










IFNγ+Foxp3+ and CD4+CD25+IFNγ+CD127- iTreg. PBL of 3 healthy
neous co-expression of TGFß and IL10 in CD4+CD25+IFNγ+Foxp3+
ometry. (a, b) 0.5% of CD4+CD25+IFNγ+Foxp3+ and 0.7% of
s TGFß as well as IL10 intracellularly, and 5% of CD4+CD25+IFNγ+Foxp3+
rcentages with respect to total of CD4+ PBL in the cell culture). Data are
n PMA/Ionomycin.
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suppression [13-16]. A recently published study showed
that Foxp3 negatively regulated CD95L expression in
Treg and demonstrated that Treg are susceptible to
homeostatic control by CD95 stimulation [17]. Our own
studies show that CD4+CD25+Foxp3+IFNγ+CD178+
human iTreg are generated during polyclonal stimula-
tion in-vitro and that they suppress alloresponses by
apoptosis of responder cells [4]. Others showed that a
distinct subset of HLA-DR+-regulatory T cells is
involved in the induction of preterm labor during preg-
nancy and in the induction of organ rejection after
transplantation [18].
Because CD4+CD25+Foxp3+ and CD4+CD25+CD127-
iTreg subsets overlap by two-thirds and represent in part
different iTreg subpopulations [8], we investigated both
subsets and particular those cells that produce intracel-
lular IFNγ. It was reported that differences in CD4+
CD25+Foxp3+ and CD4+CD25+CD127- iTreg frequen-
cies exist in the blood of patients with systemic sclero-
derma [8]. Recently, Foxp3- CD4+CD25+CD127- iTreg
with appreciable suppressive activity on effector T cell
proliferation, although less than that displayed by Treg
cells from healthy controls, were demonstrated in
patients with immune dysregulation, polyendocrinopa-
thy, enteropathy, X-linked (IPEX) syndrome [19]. Our
data show a similar reaction pattern of both iTreg sub-
sets in the presence of monoclonal antibodies against
the studied cell determinants (Figure 1), suggesting that
both subsets co-express CD178, CD152, CD28, CD95,
and HLA-DR (Figure 4). However, assays with recom-
binant protein exhibit in part divergent results of the
two iTreg populations (Figure 2).
We investigated the induction of IFNγ+ iTreg in-vitro.
This particular iTreg subset represents the first line of
iTreg during an immune response because they express
IFNγ receptors, are induced by IFNγ, and represent sen-
sors for immediate immune responses [2]. IFNγ-
producing CD4+CD25+Foxp3+ PBL were associated with
good long-term graft outcome in renal transplant recipi-
ents and suppressed alloresponses in-vitro [1,2]. Others
reported similar findings in mice. Mouse iTreg gener-
ated by IFNγ-conditioning of non-regulatory CD4+ T
cells in the presence of alloantigen not only prevented
the acute rejection of skin and islet allografts, but also
the development of chronic allograft dysfunction
(CAD)-associated vasculopathy of an arterial transplant
[20-23].Conclusion
Our data suggest that CD28, CD95, CD152, CD178,
CD278, and HLA-DR interactions are necessary for the
induction and suppressive function of IFNγ+ iTreg.Methods
Healthy controls
Laboratory staff served as healthy controls. All controls
gave informed consent for the tests performed within
this study and the study was approved by the local eth-
ical committee “Ethikkommission, Medizinische Fakultät
Heidelberg”. The study was conducted in adherence to
the Declaration of Helsinki.
Polyclonal stimulation of PBL
PBL were separated from heparinized whole blood by
Ficoll density gradient centrifugation and stimulated for
16 h using a mixture of phorbol 12-myristate 13-acetate
(PMA; final concentration in medium: 10 ng/ml; Sigma
Aldrich, Munich, Germany) and ionomycin (1 μg/ml;
Sigma Aldrich, Munich, Germany), or for 3 days using
either PMA/Ionomycin or phytohaemagglutinin (PHA,
final concentration in medium: 10 ng/ml; Sigma Aldrich,
Munich, Germany) in RPMI medium containing 10%
FCS, L-Glutamin, and Penicillin/ Streptomycin (all from
Invitrogen Gibco, Paisley, Scotland) as described previ-
ously [2]. All tests were done in triplicate. The mean of
triplicate assays was calculated and used for statistical
analysis. Cell activation and proliferation was determined
using 3H-thymidine incorporation. Alternatively, cell
proliferation was measured using CFSE (CellTrace CFSE
Cell Proliferation Kit, Invitrogen) staining according to
the manufacturer's instruction [2].
Separation of CD4+CD25+CD127-IFNγ+ PBL from PMA/
Ionomycin-stimulated short-term cell cultures
As described previously, CD4+ PBL were separated by
negative selection using biotinylated monoclonal anti-
bodies against CD14, CD16, CD56, CD123, CD36, CD8,
CD19, glycophorin (Dynabeads Regulatory CD4+CD25+
T cell kit, Invitrogen, Dynal Oslo, Norway), CD127 (BD
Biosciences, Heidelberg, Germany), and streptavidin-
coupled beads according to the manufacturer's ins-
tructions [2]. CD4+CD127- PBL were incubated with bead-
coupled CD25 monoclonal antibodies and CD4+CD127-
CD25+ PBL were separated using a magnet. CD25 mono-
clonal antibodies were removed from the cell surface
by addition of anti-Fab antibody (DETACHaBEAD,
Invitrogen). CD4+CD25+CD127- PBL were incubated
with a biotinylated IFNγ monoclonal antibody (BD
Biosciences, Heidelberg, Germany, clone 4S.B3) (20 μl
antibody to 500 μl cell suspension) for 20 min. Thereafter,
CD4+CD25+CD127-IFNγ+ PBL were separated from
CD4+CD25+CD127-IFNγ- PBL using streptavidin-
coupled beads (Dynabeads Biotin Binder, Invitrogen).
Separated PBL were added to co-cultures of autologous
PBL stimulated for another 3 days with PMA/Ionomycin
in the presence or absence of monoclonal antibodies
against cell surface molecules.
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http://www.biomedcentral.com/1471-2172/13/47Co-cultures of PMA/Ionomycin-stimulated PBL with
autologous separated CD4+CD25+CD127-IFNγ+ and
CD4+CD25+CD127-IFNγ- PBL in the presence or absence
of monoclonal antibodies
106 PBL (100 μl) were co-cultured with 105 separated
CD4+CD25+CD127-IFNγ+ or CD4+CD25+CD127-IFNγ-
PBL (100 μl). Monoclonal antibody was added to the
co-cultures (final concentration 1 μg/ml). At the end
of the culture period, PBL were pulsed with 20 μl of
3 H-thymidine (1 mCi/ml) per well for 16 h. Cells were
harvested and 3H-thymidine incorporation was mea-
sured using a ß-counter.Determination of PBL subsets
PBL subsets were determined as described previously
[1]. For analysis of determinants on the cell surface, PBL
were incubated with fluorochrome-labelled monoclonal
antibodies against CD4, CD25, CD127, CD178, CD152,
CD279, CD28, CD95, and HLA-DR (all from BD Bios-
ciences). Intracellular determinants/cytokines were
stained with fluorochrome-labelled monoclonal anti-
bodies against Foxp3, IFNγ (clone B27), IL4, IL10 (all from
BD Biosciences), and TGFß (R&D systems, Wiesbaden,
Germany). Briefly, PBL were incubated with combinations
of monoclonal antibodies for 30 min as described. Multi-
color fluorescence was analyzed using a FACScalibur dual-
laser, a FACScanto triple-laser, or a LSR II four-laser
flow-cytometer (all BD Biosciences) [1]. When, in addition,
intracellular proteins were studied, cell membranes
were permeabilized using BD Perm/Wash buffer (BD
Biosciences). At least 100,000 events were analyzed in the
initial FSC/SSC dot plot. IFNγ monoclonal antibody used
for cell separation (BD clone 4S.B3) and IFNγ monoclonal
antibody used for cell staining (BD clone B27) were not
competitive (data not shown) [2].Statistics
For statistical analysis, PASW Statistics program version
18 (IBM, Chicago, Illinois, USA) and Wilcoxon signed
rank test were used. P-values of less than 0.05 were con-
sidered significant.
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